Swiss National Bank I Mab Transaction History

Swiss National Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$8.27 - $18.43 $836,510 - $1.86 Million	-101,150 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$12.54 - $46.93 $203,148 - $760,266	16,200 Added 19.07%	101,150 $1.64 Million
Q4 2021 Feb 08, 2022	BUY	$45.28 - $74.5 $520,720 - $856,750	11,500 Added 15.66%	84,950 $4.03 Million
Q2 2021 Aug 06, 2021	BUY	$47.86 - $83.95 $3.52 Million - $6.17 Million	73,450 New	73,450 $6.17 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $88.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.